| |
 |
NEWS & PUBLICATIONS: PRESS RELEASES |
|
|
|
|
| |
| August 2, 2010 |
Taligen Therapeutics announces that data on three of its pipeline drugs will be highlighted at the XXIII International Complement Workshop |
| June 23, 2010 |
Taligen Therapeutics receives Bioscience Company of the Year Award from the University of Colorado and Taligen CSO, Michael Holers, is honored with Lifetime Achievement Award |
| April 15, 2010 |
Taligen Therapeutics announces the addition of Sven Ante (Bill) Lundberg, MD as Chief Medical Officer and Karen Tubridy, PharmD, as Vice President, Clinical Operations and Regulatory Affairs |
| April 15, 2010 |
Taligen Therapeutics announces the appointment of John Maraganore, Ph.D., CEO of Alnylam Pharmaceuticals, to its Board of Directors |
| November 10, 2009 |
Taligen Therapeutics Announces that TT30, a Novel Protein Targeting the Complement System, will be Highlighted in Two Presentations at the American Society of Hematology Meeting |
| December 5, 2008 |
Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer |
| October 6, 2008 |
In Vivo Data on Taligen Therapeutics’ Pipeline Candidates Presented at the XXII International Complement Workshop |
| September 25, 2008 |
Data from In Vivo Disease Models on Taligen Therapeutics’ Pipeline Candidates to be Presented at the XXII International Complement Workshop |
| July 23, 2008 |
Taligen Therapeutics Initiates Corporate Growth Plan |
| February 1, 2008 |
Taligen Therapeutics Secures Series B Financing |
| August 1, 2006 |
Taligen Therapeutics Announces Successful Achievement of Series A Milestone |
|
|
|
